Comparison of Rapamycin- and Paclitaxel-Eluting Stents in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

American Journal of Cardiology

Volumn 104, Issue 2, 2009, Pages 205-209

  Juwana, Yahya B ^a   Suryapranata, Harry ^b   Ottervanger, Jan Paul ^b   De Luca, Giuseppe ^b   van't Hof, Arnoud W J ^b   Dambrink, Jan Henk E ^b   de Boer, Menko Jan ^b   Gosselink, A T Marcel ^b   Hoorntje, Jan C A ^b  

^a Cardiovascular Center   (Indonesia)

^b Isala Klinieken ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXUS'; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYPHER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG FATALITY; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY ANGIOGRAPHY; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 67649344089     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.015     Document Type: Article

References (20)

1. Weaver W.D., Simes R.J., Betriu A., Grines C.L., Zijlstra F., Garcia E., Grinfeld L., Gibbons R.J., Ribeiro E.E., DeWood M.A., Ribichini F.L., and Primary Coronary Angioplasty vs Thrombolysis Collaboration Group. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative overview. JAMA 278 (1997) 2093-2098
2. Zijlstra F., Hoorntje J.C.A., de Boer M.J., Reiffers S., Miedema K., Ottervanger J.P., van't Hof A.W.J., and Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341 (1999) 1413-1419
3. Grines C.L., Browne K.F., Marco J., Rothbaum D., Stone G.W., O'Keefe J., Overlie P., Donohue B., Chelliah N., and Timmis G.C. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328 (1993) 673-679
4. O'Neill W.W., de Boer M.J., Gibbons R.J., Holmes D.R., Timmis G.C., Sachs D., Grines C.L., and Zijlstra F. Lessons from the pooled outcome of the PAMI, ZWOLLE and Mayo Clinic randomized trials of primary angioplasty versus thrombolytic therapy of acute myocardial infarction. J Invasive Cardiol 10 suppl A (1998) 4A-10A
5. Suryapranata H., van't Hof A.W.J., Hoorntje J.C.A., de Boer M.J., and Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in patients with acute myocardial infarction. Circulation 97 (1998) 2502-2507
6. Grines C.L., Cox D.A., Stone G.W., Garcia E., Mattos L.A., Giambartolomei A., Brodie B.R., Madonna O., Eijgelshoven M., Lansky A.J., O'Neill W.W., Morice M.C., and Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 341 (1999) 1949-1956
7. De Luca G., Suryapranata H., Stone G.W., Antoniucci D., Biondi-Zoccai G., Kastrati A., Chiariello M., and Marino P. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 126 (2008) 37-44
8. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabaté M., Suttorp M.J., Baumgart D., Seyfarth M., Pfisterer M.E., and Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
9. Melfi R., Nusca A., Patti G., and Di Sciascio G. The risks and benefits of drug-eluting stents in the setting of STEMI. Curr Cardiol Rep 10 (2008) 402-406
10. De Luca G., Valgimigli M., Spaulding C., Menichelli M., Rocca H.P., van der Hoeven B.L., Di Lorenzo E., de la Llera L.S., Pasceri V., Pittl U., Percoco G., Violini R., and Stone G.W. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis (2009)
11. Schömig A., Dibra A., Windecker S., Mehilli J., Suárez de Lezo J., Kaiser C., Park S.J., Goy J.J., Lee J.H., Di Lorenzo E., Wu J., Jüni P., Pfisterer M.E., Meier B., and Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1373-1380
12. Windecker S., Remondino A., Eberli F.R., Jüni P., Räber L., Wenaweser P., Togni M., Billinger M., Tüller D., Seiler C., Roffi M., Corti R., Sütsch G., Maier W., Lüscher T., Hess O.M., Egger M., and Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
13. Kastrati A., Mehilli J., von Beckerath N., Dibra A., Hausleiter J., Pache J., Schühlen H., Schmitt C., Dirschinger J., Schömig A., and ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
14. Morice M.C., Colombo A., Meier B., Serruys P., Tamburino C., Guagliumi G., Sousa E., Stoll H.P., and REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
15. Galløe A.M., Thuesen L., Kelbaek H., Thayssen P., Rasmussen K., Hansen P.R., Bligaard N., Saunamäki K., Junker A., Aarøe J., Abildgaard U., Ravkilde J., Engstrøm T., Jensen J.S., Andersen H.R., Bøtker H.E., Galatius S., Kristensen S.D., Madsen J.K., Krusell L.R., Abildstrøm S.Z., Stephansen G.B., Lassen J.F., and SORT OUT II Investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 299 (2008) 409-416
16. Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Farhat N., Mahaffey K.W., Cutlip D.E., Fitzgerald P.J., Sood P., Su X., Lansky A.J., and SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
17. Lee J.H., Kim H.S., Lee S.W., Park J.H., Cho S.W., Jeong J.O., Cho Y., Lee N., Rhee K.S., Ko J.K., and Seong I.W. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 72 (2008) 25-32
18. Daemen J., Tanimoto S., García-García H.M., Kukreja N., van de Sande M., Sianos G., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH registries). Am J Cardiol 99 (2007) 1027-1032
19. Parry T.J., Brosius R., Thyagarajan R., Carter D., Argentieri D., Falotico R., and Siekierka J. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 524 (2005) 19-29
20. Jensen L.O., Maeng M., Thayssen P., Christiansen E.H., Hansen K.N., Galloe A., Kelbaek H., Lassen J.F., and Thuesen L. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting stent (DiabeDES) intravascular ultrasound trial. Eur Heart J 29 (2008) 2733-2741